Zacks: Brokerages Set $6.33 Target Price for Soligenix, Inc. (NASDAQ:SNGX)
Soligenix, Inc. (NASDAQ:SNGX) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Analysts have set a one year consensus price objective of $6.33 for the company and are forecasting that the company will post ($0.10) earnings per share for the current quarter, according to Zacks. Zacks has also given Soligenix an industry rank of 51 out of 254 based on the ratings given to its competitors.
Several equities research analysts have issued reports on SNGX shares. ValuEngine upgraded Soligenix from a “sell” rating to a “hold” rating in a report on Thursday, April 2nd. Maxim Group started coverage on shares of Soligenix in a research note on Thursday. They set a “buy” rating and a $4.00 price objective on the stock.
The business has a 50 day moving average price of $1.86 and a two-hundred day moving average price of $1.95. Soligenix has a 1-year low of $0.70 and a 1-year high of $3.54.
Soligenix (NASDAQ:SNGX) last announced its earnings results on Friday, May 15th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.21). Soligenix had a negative return on equity of 542.83% and a negative net margin of 351.69%. The business had revenue of $0.90 million for the quarter. Equities analysts expect that Soligenix will post -0.49 earnings per share for the current fiscal year.
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Featured Story: The Discount Rate – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.